The impact of overall obesity on serotonin level in the acute phase of coronavirus infection and post-coronavirus sequelae: aspects of neuropsychological and cognitive impairments
DOI:
https://doi.org/10.14739/2310-1210.2023.5.277230Keywords:
COVID-19, serotonin, complications, cognitive disorders, psycho-emotional disorders, quality of life, obesityAbstract
Aim: to study the relationship between neurotransmitter support and the degree of cognitive and psycho-emotional impairments in patients in the post-coronavirus period depending on the presence of overall obesity.
Materials and methods. 44 patients aged 19 to 76 years (17 women and 27 men) with a history of moderate-to-severe COVID-19 were examined. 2 groups were allocated depending on body mass index (BMI): Group 1 – 20 non-obese patients (BMI <30 kg/m2; male / female 10/10); Group 2 – 24 obese people (BMI ≥30 kg/m2; male / female 17/7). The groups of subjects were comparable in age, length of hospital stay, severity of COVID-19, hematological and biochemical parameters, C-reactive protein, D-dimer. Parameters of quality of life (QL), psycho-emotional state, and cognitive function were studied by a questionnaire method 6 months after recovery.
Results. It has been found that the serotonin level was significantly lower in the acute period of infection in the group of obese patients compared to that in the non-obese group. However, after treatment, serum serotonin returned to reference values. No significant differences were detected between the two groups of patients regarding the values of neurocognitive and social parameters in the post-COVID period. Correlation analysis has shown that QL scores in Group 1 were positively correlated with cognitive function (r from 0.54 to 0.73) and negatively – with anxiety and depression (r from -0.60 to -0.80). In Group 2, the serotonin level was positively correlated with self-assessments of the QL (r from 0.42 to 0.53) and negatively – with cognitive abilities and anxiety (r from -0.51 to -0.60).
Conclusions. The presence of obesity (BMI ≥30 kg/m2) in patients with COVID-19 was accompanied by reduced serum serotonin levels during the acute phase of COVID-19. In the post-COVID period, the initial level of serotonin in obese patients was correlated with the deterioration of quality of life and worsening cognitive function assessments.
References
Hüfner, K., Tymoszuk, P., Ausserhofer, D., Sahanic, S., Pizzini, A., Rass, V., Galffy, M., Böhm, A., Kurz, K., Sonnweber, T., Tancevski, I., Kiechl, S., Huber, A., Plagg, B., Wiedermann, C. J., Bellmann-Weiler, R., Bachler, H., Weiss, G., Piccoliori, G., Helbok, R., … Sperner-Unterweger, B. (2022). Who Is at Risk of Poor Mental Health Following Coronavirus Disease-19 Outpatient Management? Frontiers in medicine, 9, 792881. https://doi.org/10.3389/fmed.2022.792881
Anderson, G., & Reiter, R. J. (2020). Melatonin: Roles in influenza, Covid-19, and other viral infections. Reviews in medical virology, 30(3), e2109. https://doi.org/10.1002/rmv.2109
Yuki, K., Fujiogi, M., & Koutsogiannaki, S. (2020). COVID-19 pathophysiology: A review. Clinical immunology, 215, 108427. https://doi.org/10.1016/j.clim.2020.108427
Aghayan, S. S., Farajzadeh, A., Bagheri-Hosseinabadi, Z., Fadaei, H., Yarmohammadi, M., & Jafarisani, M. (2020). Elevated homocysteine, as a biomarker of cardiac injury, in panic disorder patients due to oxidative stress. Brain and behavior, 10(12), e01851. https://doi.org/10.1002/brb3.1851
Nataf, S. (2020). An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. Journal of medical virology, 92(10), 1743-1744. https://doi.org/10.1002/jmv.25826
Antonini, A., Leta, V., Teo, J., & Chaudhuri, K. R. (2020). Outcome of Parkinson's Disease Patients Affected by COVID-19. Movement disorders, 35(6), 905-908. https://doi.org/10.1002/mds.28104
Collantes, M. E., Espiritu, A. I., Sy, M. C., Anlacan, V. M., & Jamora, R. D. (2021). Neurological Manifestations in COVID-19 Infection: A Systematic Review and Meta-Analysis. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 48(1), 66-76. https://doi.org/10.1017/cjn.2020.146
Xu, Y., Zhuang, Y., & Kang, L. (2021). A Review of Neurological Involvement in Patients with SARS-CoV-2 Infection. Medical science monitor, 27, e932962. https://doi.org/10.12659/MSM.932962
Attademo, L., & Bernardini, F. (2021). Are dopamine and serotonin involved in COVID-19 pathophysiology?. The European journal of psychiatry, 35(1), 62–63. https://doi.org/10.1016/j.ejpsy.2020.10.004.
Zhang, Q., Chen, D., Shen, Y., Bian, M., Wang, P., & Li, J. (2021). Incidence and Prevalence of Poststroke Shoulder Pain Among Different Regions of the World: A Systematic Review and Meta-Analysis. Frontiers in neurology, 12, 724281. https://doi.org/10.3389/fneur.2021.724281
Santos, A. P., Couto, C. F., Pereira, S. S., & Monteiro, M. P. (2022). Is Serotonin the Missing Link between COVID-19 Course of Severity in Patients with Diabetes and Obesity?. Neuroendocrinology, 112(11), 1039-1045. https://doi.org/10.1159/000522115
Machhi, J., Herskovitz, J., Senan, A. M., Dutta, D., Nath, B., Oleynikov, M. D., Blomberg, W. R., Meigs, D. D., Hasan, M., Patel, M., Kline, P., Chang, R. C., Chang, L., Gendelman, H. E., & Kevadiya, B. D. (2020). The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. Journal of neuroimmune pharmacology, 15(3), 359-386. https://doi.org/10.1007/s11481-020-09944-5
Páramo, J. A. (2022). Inflammatory response in relation to COVID-19 and other prothrombotic phenotypes. Reumatologia clinica, 18(1), 1-4. https://doi.org/10.1016/j.reumae.2020.06.007
Eteraf-Oskouei, T., & Najafi, M. (2022). The relationship between the serotonergic system and COVID-19 disease: A review. Heliyon, 8(5), e09544. https://doi.org/10.1016/j.heliyon.2022.e09544
Molgora, S., Saita, E., Barbieri Carones, M., Ferrazzi, E., & Facchin, F. (2022). Predictors of Postpartum Depression among Italian Women: A Longitudinal Study. International journal of environmental research and public health, 19(3), 1553. https://doi.org/10.3390/ijerph19031553
Wu, Y., Xu, X., Chen, Z., Duan, J., Hashimoto, K., Yang, L., Liu, C., & Yang, C. (2020). Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain, behavior, and immunity, 87, 18-22. https://doi.org/10.1016/j.bbi.2020.03.031
Al-Sabah, S., Al-Haddad, M., Al-Youha, S., Jamal, M., & Almazeedi, S. (2020). COVID-19: Impact of obesity and diabetes on disease severity. Clinical obesity, 10(6), e12414. https://doi.org/10.1111/cob.12414
Nicholson, J. K., Holmes, E., Kinross, J. M., Darzi, A. W., Takats, Z., & Lindon, J. C. (2012). Metabolic phenotyping in clinical and surgical environments. Nature, 491(7424), 384-392. https://doi.org/10.1038/nature11708
Rundblad, A., Christensen, J. J., Hustad, K. S., Bastani, N. E., Ottestad, I., Holven, K. B., & Ulven, S. M. (2023). Associations between dietary intake and glucose tolerance in clinical and metabolomics-based metabotypes. Genes & nutrition, 18(1), 3. https://doi.org/10.1186/s12263-023-00721-6
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
